Advertisement

Topics

MiMedx to Divest Biologics Subsidiary to Focus on Biopharma

05:30 EDT 21 Aug 2017 | PharmPro

MiMedx signs definitive agreement to divest Stability Biologics subsidiary as part of company's strategic focus on biopharma. MiMedx says it expects to have better ROI opportunities in biopharma compared to those in the cadaver tissue category.
Contributed Author: 
MiMedx Group, Inc.
Topics: 

Original Article: MiMedx to Divest Biologics Subsidiary to Focus on Biopharma

NEXT ARTICLE

More From BioPortfolio on "MiMedx to Divest Biologics Subsidiary to Focus on Biopharma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...